CN102655753A - 组合药 - Google Patents
组合药 Download PDFInfo
- Publication number
- CN102655753A CN102655753A CN2010800466406A CN201080046640A CN102655753A CN 102655753 A CN102655753 A CN 102655753A CN 2010800466406 A CN2010800466406 A CN 2010800466406A CN 201080046640 A CN201080046640 A CN 201080046640A CN 102655753 A CN102655753 A CN 102655753A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compd
- compound
- cell
- suitably
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC=C*[C@](*=ICF)F Chemical compound CC=C*[C@](*=ICF)F 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Abstract
Description
来源 | 细胞系 | MAPK | PI3K/PTEN | 具有(w)EOHSA的组合药#(评估的264个组合药) | % |
皮肤 | A375P | BRAFV600E | WT/WT | 34 | 13 |
结肠 | RKO | BRAFV600E | mut/WT | 111 | 43 |
皮肤 | A101D | BRAFV600E | WT/mut | 26 | 10 |
皮肤 | SK-MEL-5 | BRAFV600E NRASG12V | WT/inc | 40 | 16 |
肺 | A-549 | KRASG12S | WT/WT | 49 | 19 |
结肠 | LoVo | KRASG13D | WT/WT | 71 | 28 |
结肠 | HCT116 | KRASG13D | mut/WT | 57 | 22 |
皮肤 | SK-MEL-2 | NRASQ61R | WT/WT | 75 | 29 |
肺 | H1299 | NRASQ61R | WT/WT | 62 | 24 |
肉瘤 | HT-1080 | NRASQ61K | WT/WT | 72 | 28 |
*** | MDA-MB-231 | NRASQ61K | WT/WT | 74 | 29 |
来源 | 细胞系 | MAPK | PI3K/PTEN | 建立(est.)临床浓度下具有(w) EOHSA的组合药的#(评估25个组合药) | % |
皮肤 | A375P | BRAFV600E | WT/WT | 16 | 64 |
结肠 | RKO | BRAFV600E | mut/WT | 23 | 92 |
皮肤 | A101D | BRAFV600E | WT/mut | 17 | 68 |
皮肤 | SK-MEL-5 | BRAFV600E NRASG12V | WT/inc | 21 | 84 |
肺 | A-549 | KRASG12S | WT/WT | 17 | 68 |
结肠 | LoVo | KRASG13D | WT/WT | 6 | 24 |
结肠 | HCT116 | KRASG13D | mut/WT | 7 | 28 |
皮肤 | SK-MEL-2 | NRASQ61R | WT/WT | 1 | 4 |
肺 | H1299 | NRASQ61R | WT/WT | 8 | 32 |
肉瘤 | HT-1080 | NRASQ61K | WT/WT | 3 | 12 |
*** | MDA-MB-231 | NRASQ61K | WT/WT | 5 | 20 |
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25221309P | 2009-10-16 | 2009-10-16 | |
US61/252213 | 2009-10-16 | ||
PCT/US2010/052808 WO2011047238A1 (en) | 2009-10-16 | 2010-10-15 | Combination |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102655753A true CN102655753A (zh) | 2012-09-05 |
CN102655753B CN102655753B (zh) | 2015-11-25 |
Family
ID=43876568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080046640.6A Active CN102655753B (zh) | 2009-10-16 | 2010-10-15 | 组合药 |
Country Status (33)
Country | Link |
---|---|
US (3) | US8703781B2 (zh) |
EP (3) | EP4159217A1 (zh) |
JP (1) | JP5718929B2 (zh) |
KR (1) | KR101729116B1 (zh) |
CN (1) | CN102655753B (zh) |
AU (1) | AU2010306653B2 (zh) |
BR (1) | BR112012008854B8 (zh) |
CA (1) | CA2775803C (zh) |
CL (1) | CL2012000964A1 (zh) |
CO (1) | CO6531498A2 (zh) |
CR (1) | CR20120155A (zh) |
CY (1) | CY1122013T1 (zh) |
DK (2) | DK2488033T3 (zh) |
DO (1) | DOP2012000091A (zh) |
EA (1) | EA020589B1 (zh) |
ES (2) | ES2745479T3 (zh) |
HR (2) | HRP20221304T1 (zh) |
HU (2) | HUE060206T2 (zh) |
IL (1) | IL219073A (zh) |
LT (2) | LT2488033T (zh) |
MA (1) | MA33746B1 (zh) |
ME (1) | ME03497B (zh) |
MX (1) | MX2012004413A (zh) |
MY (1) | MY174759A (zh) |
NZ (1) | NZ598913A (zh) |
PE (1) | PE20121093A1 (zh) |
PL (2) | PL2488033T3 (zh) |
PT (2) | PT3560498T (zh) |
RS (2) | RS59181B1 (zh) |
SI (1) | SI2488033T1 (zh) |
UA (1) | UA105064C2 (zh) |
WO (1) | WO2011047238A1 (zh) |
ZA (1) | ZA201202612B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588767A (zh) * | 2013-11-20 | 2014-02-19 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
CN104540822A (zh) * | 2013-07-08 | 2015-04-22 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
CN104812391A (zh) * | 2012-10-25 | 2015-07-29 | 葛兰素史克公司 | 组合 |
CN104902876A (zh) * | 2012-11-30 | 2015-09-09 | 葛兰素史克公司 | 新型药物组合物 |
CN105163584A (zh) * | 2013-03-05 | 2015-12-16 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
CN105658206A (zh) * | 2013-06-03 | 2016-06-08 | 诺华股份有限公司 | 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合 |
CN106029074A (zh) * | 2013-12-12 | 2016-10-12 | 诺华股份有限公司 | 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
EP3289876B1 (en) | 2008-06-16 | 2022-07-20 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
MX343368B (es) * | 2010-03-09 | 2016-11-01 | The Broad Inst Inc * | Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer. |
JP2014505658A (ja) * | 2010-11-05 | 2014-03-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌を治療する方法 |
TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
WO2013087914A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
JP2015503503A (ja) * | 2011-12-22 | 2015-02-02 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Braf阻害剤および/またはmek阻害剤とともにmagea3免疫療法薬を用いた癌の治療方法 |
CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
PT2892535T (pt) * | 2012-09-04 | 2021-12-15 | Novartis Ag | Método de tratamento adjuvante do cancro |
CN103965170A (zh) * | 2013-01-24 | 2014-08-06 | 通化济达医药有限公司 | 苯磺酰胺吡唑激酶抑制剂 |
ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
WO2015059677A1 (en) * | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
CN111534580A (zh) | 2013-12-28 | 2020-08-14 | 夸登特健康公司 | 用于检测遗传变异的方法和*** |
WO2015105822A1 (en) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Cancer treatment method |
EP3708164A1 (en) | 2014-05-06 | 2020-09-16 | Oncternal Therapeutics, Inc | Compounds for treatment of cancer |
KR101629184B1 (ko) | 2014-12-10 | 2016-06-13 | 현대오트론 주식회사 | Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법 |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
JP2019537604A (ja) * | 2016-11-03 | 2019-12-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Egfr/pi3kの小分子二重阻害剤及びその使用 |
JP2022504905A (ja) | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷 |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
JP2022501394A (ja) * | 2019-07-26 | 2022-01-06 | アセンテージ ファーマ(スーチョウ)カンパニー,リミティド | Mdm2阻害剤の医薬組成物、並びに疾患を予防及び/又は治療するためのその使用 |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics Llc | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021168283A1 (en) * | 2020-02-19 | 2021-08-26 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
AU2022381730A1 (en) * | 2021-11-02 | 2024-05-02 | Verastem, Inc. | Methods of treating abnormal cell growth |
WO2023105286A1 (en) | 2021-12-06 | 2023-06-15 | My Personal Therapeutics Ltd | A combination treatment for cancer |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005121142A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
US7026336B1 (en) * | 1999-11-22 | 2006-04-11 | Smithkline Beecham P.L.C. | Compounds |
US20070244135A1 (en) * | 2004-04-15 | 2007-10-18 | Guenter Hoelzemann | Sulfonamides |
WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
CA2694646C (en) | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
-
2010
- 2010-10-15 PT PT191745942T patent/PT3560498T/pt unknown
- 2010-10-15 ES ES10824148T patent/ES2745479T3/es active Active
- 2010-10-15 RS RSP20191095 patent/RS59181B1/sr unknown
- 2010-10-15 RS RS20220984A patent/RS63702B1/sr unknown
- 2010-10-15 PE PE2012000502A patent/PE20121093A1/es active IP Right Grant
- 2010-10-15 EP EP22189749.9A patent/EP4159217A1/en active Pending
- 2010-10-15 US US13/499,779 patent/US8703781B2/en active Active
- 2010-10-15 BR BR112012008854A patent/BR112012008854B8/pt active IP Right Grant
- 2010-10-15 EP EP19174594.2A patent/EP3560498B1/en active Active
- 2010-10-15 DK DK10824148.0T patent/DK2488033T3/da active
- 2010-10-15 MY MYPI2012001680A patent/MY174759A/en unknown
- 2010-10-15 UA UAA201204675A patent/UA105064C2/uk unknown
- 2010-10-15 CN CN201080046640.6A patent/CN102655753B/zh active Active
- 2010-10-15 HU HUE19174594A patent/HUE060206T2/hu unknown
- 2010-10-15 DK DK19174594.2T patent/DK3560498T3/da active
- 2010-10-15 PL PL10824148T patent/PL2488033T3/pl unknown
- 2010-10-15 JP JP2012534386A patent/JP5718929B2/ja active Active
- 2010-10-15 NZ NZ598913A patent/NZ598913A/xx unknown
- 2010-10-15 PL PL19174594.2T patent/PL3560498T3/pl unknown
- 2010-10-15 ME MEP-2019-236A patent/ME03497B/me unknown
- 2010-10-15 HU HUE10824148A patent/HUE046139T2/hu unknown
- 2010-10-15 WO PCT/US2010/052808 patent/WO2011047238A1/en active Application Filing
- 2010-10-15 EA EA201290149A patent/EA020589B1/ru not_active IP Right Cessation
- 2010-10-15 PT PT10824148T patent/PT2488033T/pt unknown
- 2010-10-15 AU AU2010306653A patent/AU2010306653B2/en active Active
- 2010-10-15 SI SI201031933T patent/SI2488033T1/sl unknown
- 2010-10-15 CA CA2775803A patent/CA2775803C/en active Active
- 2010-10-15 MX MX2012004413A patent/MX2012004413A/es active IP Right Grant
- 2010-10-15 KR KR1020127012649A patent/KR101729116B1/ko active IP Right Grant
- 2010-10-15 EP EP10824148.0A patent/EP2488033B1/en active Active
- 2010-10-15 LT LTEP10824148.0T patent/LT2488033T/lt unknown
- 2010-10-15 HR HRP20221304TT patent/HRP20221304T1/hr unknown
- 2010-10-15 LT LTEP19174594.2T patent/LT3560498T/lt unknown
- 2010-10-15 ES ES19174594T patent/ES2930157T3/es active Active
-
2012
- 2012-03-27 CR CR20120155A patent/CR20120155A/es unknown
- 2012-04-03 DO DO2012000091A patent/DOP2012000091A/es unknown
- 2012-04-05 IL IL219073A patent/IL219073A/en active IP Right Grant
- 2012-04-11 ZA ZA2012/02612A patent/ZA201202612B/en unknown
- 2012-04-16 CL CL2012000964A patent/CL2012000964A1/es unknown
- 2012-04-27 CO CO12069732A patent/CO6531498A2/es active IP Right Grant
- 2012-05-11 MA MA34863A patent/MA33746B1/fr unknown
-
2014
- 2014-03-05 US US14/197,421 patent/US8952018B2/en active Active
- 2014-12-22 US US14/578,804 patent/US20150111904A1/en not_active Abandoned
-
2019
- 2019-09-06 HR HRP20191617 patent/HRP20191617T1/hr unknown
- 2019-09-09 CY CY20191100943T patent/CY1122013T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026336B1 (en) * | 1999-11-22 | 2006-04-11 | Smithkline Beecham P.L.C. | Compounds |
US20070244135A1 (en) * | 2004-04-15 | 2007-10-18 | Guenter Hoelzemann | Sulfonamides |
WO2005121142A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104812391A (zh) * | 2012-10-25 | 2015-07-29 | 葛兰素史克公司 | 组合 |
CN104902876A (zh) * | 2012-11-30 | 2015-09-09 | 葛兰素史克公司 | 新型药物组合物 |
CN104902876B (zh) * | 2012-11-30 | 2018-01-19 | 葛兰素史克公司 | 新型药物组合物 |
CN107970214A (zh) * | 2012-11-30 | 2018-05-01 | 葛兰素史克公司 | 新型药物组合物 |
CN105163584A (zh) * | 2013-03-05 | 2015-12-16 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
CN105163584B (zh) * | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
CN105658206A (zh) * | 2013-06-03 | 2016-06-08 | 诺华股份有限公司 | 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合 |
CN104540822A (zh) * | 2013-07-08 | 2015-04-22 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
CN104540822B (zh) * | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
CN103588767A (zh) * | 2013-11-20 | 2014-02-19 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
CN103588767B (zh) * | 2013-11-20 | 2016-01-20 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
CN106029074A (zh) * | 2013-12-12 | 2016-10-12 | 诺华股份有限公司 | 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102655753A (zh) | 组合药 | |
AU2013334599B2 (en) | Combination | |
CN106029074A (zh) | 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合 | |
CN106061481B (zh) | 用于治疗癌症的雄激素受体抑制剂与akt抑制剂的组合 | |
CN101662937A (zh) | 癌症治疗方法 | |
CN104902876A (zh) | 新型药物组合物 | |
CN105530934A (zh) | 组合药物疗法 | |
CN109674801A (zh) | 组合 | |
CN104902896A (zh) | 组合 | |
CN106456642A (zh) | 含btk抑制剂与akt抑制剂的组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160422 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: NOVA LABORATORIES SDN BHD Effective date of registration: 20160422 Address after: Basel, Switzerland Patentee after: NOVA LABORATORIES SDN BHD Address before: British Ahmed Sykes Patentee before: Glaxo Group Ltd. Effective date of registration: 20160422 Address after: British Ahmed Sykes Patentee after: GLAXO Group Ltd. Address before: American Pennsylvania Patentee before: GlaxoSmithKline LLC |